Search results
Showing 1126 to 1140 of 1346 results for long term conditions
Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)
NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS175Show all sections
Sections for QS175
- Quality statements
- Quality statement 1: Early assessment and treatment
- Quality statement 2: Discussion about psychological treatment options
- Quality statement 3: First-line psychological treatment for binge eating disorder
- Quality statement 4: Bulimia-nervosa-focused family therapy
- Quality statement 5: Coordinated care across services
- Quality statement 6: Risk assessment when moving between services
- Update information
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections